Suggested remit: To appraise the clinical and cost effectiveness of cemiplimab with chemotherapy within its marketing authorisation for untreated advanced or metastatic NSCLC.
Status In progress
Technology type Medicine
Decision Selected
Process STA Standard
ID number 3949

Email enquiries


Key events during the development of the guidance:

Date Update
25 April 2024 Please note that following on from conversation between NICE and the company, the timelines for this appraisal have been scheduled and the appraisal is now anticipated to begin in early July 2024 when we will write to you about how you can get involved.
13 February 2024 - 12 March 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 3949
13 February 2024 In progress. Scoping commencing
18 August 2022 Suspended. As you will be aware, the Department for Health & Social Care has asked NICE to carry out a Single Technology Appraisal of Cemiplimab with chemotherapy for untreated advanced or metastatic non-small-cell lung cancer [ID3949]. For information the company have advised that they will not be making a submission. Therefore, in collaboration with the company, NICE has suspended this evaluation from its current work programme. As this evaluation has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.

For further information on our processes and methods, please see our CHTE processes and methods manual